1Tefferi A, Thiele J, Orazi A, et al. Proposals and rationalefor re- vision of the Worm Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an adhoc international ex- pert panel[J]. Blood, 2007, 110:1 092 - 1 097.
2Rossi C, RandiML, Zerbinati P, et al. 1Acute coronary disease in essential thrombocythemia and polycythemia vera [ J ]. J Intern Med, 1998, 244 (1): 49- 531.
4Ross L, Levine, Mark Heaney. New advances in the pathogenesis and therapy of essential thrombocythemia. Hematology-Amer ican Society of Hematology, 2008,76-82.
5Chloe James. The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders=One Mutation for Three Diseases? Hematology-American Society of Hematology, 2008, 2008 : 69.
